Jennifer King, MD
Jennifer King MD
Indiana University School of Medicine
Division of Hematology & Oncology
535 Barnhill Drive, RT 473
Indianapolis, IN 46202
Phone: 317-948-0361
Email: jmstrass@iu.edu
EDUCATION
POSTDOCTORAL Degree Date Awarded
Indiana University Oncology Fellowship 2022
Indianapolis, Indiana
Indiana University Internal Medicine Residency 2019
Indianapolis, Indiana
GRADUATE
Indiana University Graduate Degree
Indianapolis, Indiana Health Innovation and 2022
Implementation Science
Indiana University MD 2016
Indianapolis, Indiana
UNDERGRADUATE
Purdue University Bachelor of Science 2012
West Lafayette, Indiana
APPOINTMENTS
ACADEMIC
Indiana University Assistant Professor of 2022-present
School of Medicine Clinical Medicine
HOSPITAL
Indiana University Health Faculty 2022-present
Richard L. Roudebush Faculty 2022-present
VA Medical Center
Eskenazi Health Consultant 2022-present
LICENSURE, CERTIFICATION, SPECIALTY BOARD STATUS
Credential Number Inclusive Dates Indiana State Medical License 01082112A 2019-present
DEA Certificate 2019-present
American Board of Internal Medicine 2019–present
PROFESSIONAL ORGANIZATION MEMBERSHIPS
Organization Inclusive Dates
American College of Physicians (ACP) 2017-present
American Society of Clinical Oncology (ASCO) 2020-present
American Association for Cancer Research (AACR) 2021-present
Hoosier Cancer Research Network (HCRN) 2022-present
Big 10 Cancer Research Consortium 2022-present
Indiana University Simon Comprehensive Cancer Center (IUSCCC) 2022-present
Associate Member
Eastern Cooperative Oncology Group (ECOG) 2023-present
Oncology Research Information Exchange Network (ORIEN)
Genitourinary Research Interest Group 2023-present
PROFESSIONAL HONORS AND AWARDS:
RESEARCH
Award Name Granted By Date Awarded
Merit Award ASCO 2021
ASCO Travel Award IUSCCC 2022
SERVICE
IUSOM Pyramid Award:
Outstanding Young Clinician Award Department of Medicine 2024
Alpha Omega Alpha Honor AOA 2015
Medical Society
EDUCATION
Internal Medicine Chief Resident Indiana University 2019-2020
PROFESSIONAL DEVELOPMENT
Course/Workshop Title Provider Date
Women in RCC Kidney Cancer Association 2024
IUSCCC Strategy and Management Indiana University 2023-2024
Succession Program
Methods in Clinical Cancer Research ASCO/AACR 2021
Health Innovation and Implementation Indiana University 2022
Science Graduate Certificate
IUSCCC, GU Multidisciplinary Indiana University 2022-present
Conference (weekly, 1 HR)
Prostate Cancer Tumor Board Indiana University 2022-present
(monthly, 1 HR)
TEACHING
MENTORING
Kirsten Lewis, MD Abstract Mentor 2023-present
Mert Svegi, MD Abstract Mentor 2023-present
Phillip Pham, MD Career/Abstract Mentor 2022-present
Ahmed Khalid, MD Career/Abstract Mentor 2022-present
Vidya Dandu, MD Career/Abstract Mentor 2022-present
Ragia Aly, MD Abstract Mentor 2022-present
Martha Cancilla Senior Seminar Mentor 2022-2023
TEACHING ADMINISTRATION AND CURRICULUM DEVELOPMENT
INVITED PRESENTATIONS – TEACHING
UNIVERSITY
“High Yield Oncology Cases”
Indiana University Internal Medicine Residency Noon Conference July 2022
“Oncologic Emergencies”
Indiana University Hematology/Oncology Fellows July 2022
“Renal Cell Carcinoma”
Clinical Trials Office Education Series October 2022
“Renal Cell Carcinoma”
Indiana University Hematology/Oncology Fellows November 2022
“Prostate Cancer”
Indiana University Hematology/Oncology Fellow Academic Half Day November 2022
“Heme Onc Emergencies”
Indiana University Pulmonary/Critical Care Fellows January 2023
“Bladder Cancer:
Indiana University Hematology/Oncology Fellows February 2023
“Systemic Therapies in Bladder and Kidney Cancer”
Indiana University Urology Residents March 2023
“Testicular Cancer”
Clinical Trials Office Education Series April 2023
“Oncology for the Internist”
Indiana University Internal Medicine/Pediatric Residents September 2023
“Management of Advanced Prostate Cancer”
Indiana University Radiation Oncology Residents October 2023
“Renal Cell Carcinoma”
Indiana University Hematology/Oncology Fellows November 2023
“Breast Cancer”
Internal Medicine Resident IMPACT Session January 2024
“Head/Neck and Lung Cancer”
Internal Medicine Resident IMPACT Session March 2024
“Bladder cancer”
Indiana University Hematology/Oncology Fellows May 2024
“Oncologic Emergencies”
Indiana University Hematology/Oncology Fellows July 2024
SERVICE
SERVICE TO THE RESEARCH MISSION
ACTIVE/SUBMITTED GRANTS/FELLOWSHIPS
ASCO Career Development Award
The implementation of a multimodality exercise intervention for patients with metastatic germ-cell tumor undergoing high-dose chemotherapy with stem-cell transplant: Assessing implementation outcomes and early efficacy on clinical outcomes
Plan to submit, 2024
SUBMITTED BUT NOT FUNDED SERVICE GRANTS/FELLOWSHIPS
Young Investigator Award
Evaluating MET expression by IHC and MET amplification by NGS in tissue samples of patients with relapsed, refractory germ-cell tumor receiving cabozantinib
2021
ASCO Career Development Award
“Cardiovascular monitoring with cardiac computed tomography with calcium score in patients with metastatic renal cell carcinoma receiving combination immunotherapy and/or tyrosine kinase inhibitors”
2022
ASCO Career Development Award
The implementation of a multimodality exercise intervention for patients with metastatic germ-cell tumor undergoing high-dose chemotherapy with stem-cell transplant: Assessing implementation outcomes and early efficacy on clinical outcomes
2023
INVITED PRESENTATIONS – SERVICE TO RESEARCH
LOCAL
“Residual non-retroperitoneal disease in nonseminomatous germ-cell tumor”
IU Simon Comprehensive Cancer Center, Grand Rounds June 2022
“Biomarkers and Novel Therapeutic Options in Genitourinary Malignancies”
IU Simon Comprehensive Cancer Center, Grand Rounds April 2022
REGIONAL
“Genitourinary Malignancies”
IUSCCC: Review and Interpretation of ASCO 2023 July 2023
“GU Cancers: Debate”
IUSCCC: Review and Interpretation of ASCO 2022 July 2022
NATIONAL
“Introduction to hematology”
ASCO Oncology Summer Internship Educational Module July 2024
UNIVERSITY SERVICE
Clinical Competency Committee Member 2024-present
Internal Medicine Residency
IUSOM Medical Student Mentoring Program Mentor 2024-present
IUSOM Internal Medicine Residency Interviewer 2023-present
Annual Program Evaluation Committee Member 2023-present
Fellowship Program Coaching Program Coach 2023-present
Associate Fellowship Hematology/Oncology Co-Associate PD 2023-present
Program Director
Key Clinical Educator, Hematology/Oncology Co-KCE 2023-present
Indiana University Scientific Review Committee Member 2023-present
IUSOM Oncology Fellowship Selection Member 2022-present
Committee
IUSOM Oncology Fellowship Interviewer 2022-present
IUSCCC Genitourinary Oncology Program Member 2022-present
IUSM Internal Medicine Residency Mentor 2022-present
Junior Faculty Special Interest Group Co-chair 2022-present
Fellowship Diversity, Equity, Inclusion Task Force Member 2022
Fellow and Faculty Call Schedule Task Force Member 2022
PROFESSIONAL SERVICE:
LOCAL
Indiana University Simon
Cancer Center Associate Member 2022-present
IUSM Internal Medicine Resident
Alumni Ambassador Member 2022-present
REGIONAL
Hoosier Cancer Research Network
GU Oncology Working Group Member 2022–present
Big Ten Cancer Research Consortium
GU Oncology Working Group Member 2022-present
HCRN Board of Directors Member 2023-present
NATIONAL
NCCN Guidelines Panel: Kidney Cancer Panel Member 2022-present
NCCN Guidelines for Patients Panel: Panel Member 2023-present
Kidney Cancer
Oncology Research Information Exchange
Network (ORIEN) GU Research Interest Group Member 2023-present
PATIENT CARE/CLINICAL SERVICE:
LOCAL
Indiana University Health Faculty 2022-present
Care for oncology patients with specific focus on genitourinary oncology (testis, prostate, bladder, kidney cancer) in both the outpatient and inpatient setting
Richard L. Roudebush VA Medical Center Faculty 2022-present
Care for oncology patients with specific focus on genitourinary oncology (testis, prostate, bladder, kidney cancer) in both the outpatient and inpatient setting, as well as serving as teaching faculty for oncology fellows in clinic
Eskenazi Health Consultant 2017-present
Care for oncology patients with specific focus on genitourinary oncology (testis, prostate, bladder, kidney cancer) in the inpatient setting
PUBLICATIONS
RESEARCH/CREATIVE ACTIVITY (refereed)
1. King J, Adra N, Einhorn L. Management of residual disease after chemotherapy in germ cell tumors. Current Opinion in Oncology. 2020; 32(3): 250-255.
2. King J, Akel R, Saliba AN, Wei C, Anouti B, et al. Innovation in resident core oncology education: Switching from an inpatient ward rotation to a hybrid model of inpatient consultations and outpatient clinics. Journal of Cancer Education. 2021; published online.
3. King J, Adra N, Einhorn LH. Testicular cancer: Biology to bedside. Cancer Research. 2021; 81: 5369-76.
4. King J, Adra N. Current status of stem cell transplant in treatment of testicular germ cell tumors. Current Oncology Reports. 2021; published online.
5. King J, Althouse S, Cary C, Masterson T, Foster RS, Ashkar R, Hanna NH, Einhorn LH, Adra N. Surveillance after complete response to first-line chemotherapy in patients with metastatic nonseminomatous germ-cell tumor. J Urology. 2022; 208(3): 641-649.
6. Tachibana I, Vasquez R, Mahmoud M, Kern SQ, Patel RS, King J, Adra N, Boris RS, Cary C, Rice KR. Can retroperitoneal lymph node dissection (RPLND) be feasibly performed to prolong survival in renal cell carcinoma (RCC) with limited lymph node involvement? An analysis of recurrence patterns. Urologic Oncology. 2022; In Press.
7. Antonelli L, Ardizzone D, Ravi P, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, Giannatempo P, Franza A, Heidenreich A, Paffenholz P, Saoud R, Eggener S, Ho M, Oswald N, Olson K, Tryakin A, Fedyanin M, Naoun N, Javaud C, Fizazi K, King J, Adra N, Douglawi A, Cary C, Sweeney C, Fankhauser CD. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumor and IGCCCG intermediate/poor prognosis: a multi-institutional retrospective cohort study. Eur Journal of Cancer. 2022; In Press.
8. King J, Cheng M, Kesler K, Ashkar R, Althouse SK, Hanna NH, Einhorn LH, Adra N. Management of residual nonretroperitoneal disease in postchemotherapy nonseminomatous germ-cell tumors. J Clin Oncol. 2023; 41(23): 3939-3944.
9. Tachibana I, Alabd A, Whaley RD, McFadden J, Piroozi A, Hassoun R, Kern SQ, King J, Adra N, Rice KR, Foster RS, Einhorn LH, Cary C, Masterson TA. Postchemotherapy retroperitoneal lymph node dissection for seminoma: Limitations of surgical intervention after first-line chemotherapy. Urologic Oncology: Seminars and Original Investigations. 2023; published online.
10. King J, Ashkar R, Kesler K, Althouse SK, Hanna NH, Einhorn LH, Adra N. Outcomes in Patients With Postchemotherapy Residual Nonretroperitoneal Disease in Nonseminomatous Germ Cell Tumors. JAMA Oncology. 2023; online ahead of print.
11. D’souza A, King J, Nappi L, Daneshmand S, Nichols C, Kollmansberg C. Favorable long-term Health Related Quality of Life in cured survivors of testicular cancer management. So, what now? Annals of Oncology. 2023; 34(12): 1077-1079.
12. Pham HM, Leung EJ, King J, O’Brien KM, Ryu JH, Claxton LJ. Controlling posture to see the world: The integration of visual task demands and postural sway in sitting and standing infants. Journal of Experimental Child Psychology. 2024; published online.
13. Ozgun G, Haney L, Kern S, King J, D’Souza A, Tandstad T, Nappi L, Kollmansberger C, Nichols CR. Once upon a time…Simple, sensible management of venous access for chemotherapy delivery in germ cell tumors. JCO Oncol Practice. 2024; 20(3): 309-310.
RESEARCH ABSTRACTS
- King J, Saliba A, Akel R, Wei C, Manchanda N, Sinex N, Grethlein S, Goldman M. Innovation in resident oncology education: Switching from an inpatient ward rotation to a hybrid model of inpatient consultations and outpatient clinics. Presented at ASCO 2020. Virtual. 2020 May 29.
- King J, Althouse S, Clary C, Masterson TA, Foster RS, Ashkar R, Hanna NH, Einhorn LH, Adra N. Surveillance after complete response (CR) in patients with metastatic non-seminomatous germ-cell tumor (NSGCT). Presented as poster discussion at ASCO 2021. Virtual. 2021 June 4.
- King J, Dropcho S, Beeler S, Kline J, Schwieterman V, Hanna NH, Einhorn LH, Adra N. A phase II trial evaluating the efficacy of cabozantinib in the treatment of patients with refractory germ-cell tumor. Presented at GU ASCO 2022. San Francisco, CA. 2022 Feb 19.
- King J. Biomarkers and Novel Therapeutic Options in Genitourinary Malignancies. Presented at Indiana University Simon Comprehensive Cancer Center Grand Rounds; Indianapolis, IN. 2022 April.
- King J, Kesler K, Ashkar R, Althouse SK, Hanna NH, Einhorn LH, Adra N. Management of residual nonretroperitoneal disease in nonseminomatous germ-cell tumors (NSGCT). Presented at ASCO 2022. Chicago, IL. 2022 June 6.
- Hassoun R, Althouse SK, King J, Hanna NH, Einhorn LH, Adra N. Primary mediastinal seminoma: Treatment and survival outcomes. Presented at GU ASCO 2023. San Francisco, CA. 2023 Feb 18.
- King J, Hassoun R, Althouse SK, Fausel C, Schneider B, Logan T, Adra N. Genomic alterations in metastatic renal cell carcinoma (mRCC): Impact on survival and clinical outcomes. Presented at GU ASCO 2023. San Francisco, CA. 2023 Feb 18.
- King J, Ashkar R, Kesler K, Althouse SK, Hanna NH, Einhorn LH, Adra N. Clinical outcomes in patients with post-chemotherapy residual non-retroperitoneal (RP) disease in non-seminomatous germ-cell tumors (NSGCT). Accepted as online publication for ASCO 2023.
- King J, Pham P, Khalid A, Sabra M, Schwartz J. Multimodality, Online Oncology Learning Resources - Meeting Residents Where They Are: A Pilot to Create a New Oncology Curriculum. Presented at ASCO 2023. Chicago, IL. 2023 June 3.
- Hassoun R, King J, Althouse SK, Hanna NH, Einhorn LH, Adra N. Bone metastasis in patients with germ-cell tumors: Analysis of survival outcomes and prognostic factors. Accepted as online publication for ASCO 2023.
- King J, Hassoun R, Althouse SK, Schneck S, Hanna NH, Einhorn LH, Adra N. Safety of pegfilgrastim in patients with metastatic germ-cell tumor receiving combination chemotherapy containing bleomycin. Presented at GU ASCO 2024. San Francisco, CA. Jan 2024.
- Hassoun R, Tann M, Sims J, Auxier A, Althouse SK, Salous T, King J, Adra N. Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer. Presented at GU ASCO 2024. San Francisco, CA. Jan 2024.
- Coulombe AM, Colby S, King J, Neuhouser M, Arun B, Daneshmand S, Harzstark A, Arnold K, Nichols C, Nappi L. North American patterns of care in clinical stage I testicular cancer from SWOG S1823. Presented at GU ASCO 2024. San Francisco, CA. Jan 2024.
- Khalid AB, Pham P, Hassoun R, Althouse SK, Abonour R, Abu Zaid M, Hanna NH, Adra N, Einhorn LH, King J. Impact of body mass index (BMI) on clinical and toxicity outcomes in paitents with relapsed metastatic germ-cell tumor (GCT) undergoing high-dose chemotherapy (HDCT) with peripheral blood stem cell transplant (PBSCT). Presented at GU ASCO 2024. San Francisco, CA. Jan 2024.
- Hassoun R, Cary C, Masterson T, Laliotis G, Sharma S, Dutta P, Malhotra M, ElNaggar A, Liu M, Sfakianos J, King J, Einhorn LH, Adra N. Utility of circulating tumor DNA (ctDNA) as a predictive biomarker for disease monitoring in patients with non-seminomatous germ-cell tumor (NSGCT). Presented at GU ASCO 2024. San Francisco, CA. Jan 2024.
- Serzan M, Jegede O, Bilen M, Braun D, Einstein D, Haas N, Hammers H, King J, Runcie K, Sosman J, Sternberg C, Yang Y, Choueiri T, Signoretti S, Atkins M. Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587). Presented at GU ASCO 2024. San Francisco, CA. Jan 2024.
- King J, Pham P, Schwartz J. Multimodality, Online Oncology Learning Resources: An Adaptable, Asynchronous Learning Resource. Presented at CGEA 2024. Milwaukee, WI. 2024 April 4.
- King J, Abonour R, Hassoun R, Althouse SK, Salous T, Hanna NH, Einhorn LH, Adra N. Management of progressive brain metastases in patients (pts) with relapsed germ-cell tumor (GCT) treated with salvage high-dose chemotherapy (HDCT). Presented at ASCO 2024. Chicago, IL. 2024 June 2.
- Aly R, Schmitt J, King J. Real-world clinical and toxicity outcomes in older Veterans with metastatic renal cell carcinoma (mRCC) treated with front-line systemic therapy. Accepted as online publication for ASCO 2024.
- Hassoun R, Tann M, Sims J, Auxier A, Althouse SK, Salous T, King J, Adra N. Xerostomia and ocular dryness as predictors of PSA response to Lu177-PSMA-617 in metastatic castration resistant prostate cancer. Accepted as online publication for ASCO 2024.
- Sevgi M, Hassoun R, Althouse SK, Tran M, Fausel CA, Schneider BP, Salous R, Adra N, King J. Clinical features, genomic alterations, and survival outcomes for variant histology urothelial carcinoma. Accepted as online publication for ASCO 2024.
- Khalid A, Hassoun R, Althouse SK, Salous T, Cary C, Masterson TA, Einhorn LH, Adra N, King J. Management of relapsed stage I nonseminomatous germ-cell tumor with retroperitoneal only relapse. Presented at ASCO 2024. Chicago, IL. 2024 June 2.
- Pham P, Hassoun R, Althouse SK, Tran M, Fausel CA, Schneider BP, Logan TF, Salous T, Adra N, King J. The impact of smoking status on genomic profile in patients with renal cell carcinoma. Accepted as online publication for ASCO 2024.
- Taza F, Tran M, Hassoun R, Althouse SK, Fausel CA, Schneider BP, Salous T, Logan TF, Adra N, King J. Genomic alterations and clinical outcomes in patients with non-clear cell RCC: Indiana University experience. Accepted as online publication for ASCO 2024.
- Hassoun R, Ben-David R, Sfakianos JP, Laliotis G, Cary C, Masterson TA, Rivero-Hinojosa S, Manage K, Dutta P, Tillu N, Cumarasamy S, King J, Rich J, Rock A, Dorff T, ElNaggar A, Liu MC, Einhorn LH, Chehrazi-Raffle A, Adra N. Longitudinal evaluation of circulating tumor DNA (ctDNA) as a prognostic biomarker to detect minimal residual disease (MRD) in testicular cancer. Presented at ASCO 2024. Chicago, IL. 2024 June 2.
- Kilari D, Szabo A, Hwang C, Ghatalia P, Rose TL, Tripathi A, Alva A, McManus HD, Basu A, Emamekhoo H, do Amaral S, Rini B, King J, Maughan B, Zakharia Y, Barata P, Desai A, Reimers M, Ged Y, Heath E, Bilen MA, Brugarolas J, McKay R. Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study. Presented at ESMO 2024. Barcelona, Spain. 17 Sept 2024.
1